Edward Nirenberg on Nostr: ACIP asked for 500 additional secondary analyses of the efficacy stratified by ...
ACIP asked for 500 additional secondary analyses of the efficacy stratified by gestational age at delivery, birth weight, and race; one of the noteworthy things about this antibody is it doesn't have weight-based dosing- everyone gets the same dose.
Published at
2024-10-23 20:57:21Event JSON
{
"id": "04598b53f0649c27326e29ddb7de63e86f5f48738ea7a54a2a6ad67dbfdb7b23",
"pubkey": "c67b38e4c5023e985f04ae7ab6a6669cf463220e1b9ed54b897d1957004603a4",
"created_at": 1729717041,
"kind": 1,
"tags": [
[
"e",
"4f1683c2621db6fc358bc7323d85e1bfeb1d43e5a602afe46c9d28589fe75821",
"wss://relay.mostr.pub",
"reply"
],
[
"proxy",
"https://med-mastodon.com/users/enirenberg/statuses/113358736053241165",
"activitypub"
]
],
"content": "ACIP asked for 500 additional secondary analyses of the efficacy stratified by gestational age at delivery, birth weight, and race; one of the noteworthy things about this antibody is it doesn't have weight-based dosing- everyone gets the same dose.",
"sig": "597bf69584930e91c066a06e5188e7e8d89fbe5949946402b7bcf29a71761b7ac5ab68ae2742d7144024dd43d3314224f69eb8a0d19c6fb0693ffd0b8a585dd5"
}
